SPRINT Stock Overview
A pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 2/6 |
Past Performance | 4/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Sprint Bioscience AB (publ) Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | SEK 1.29 |
52 Week High | SEK 3.28 |
52 Week Low | SEK 0.45 |
Beta | 0.47 |
11 Month Change | -3.73% |
3 Month Change | -4.87% |
1 Year Change | 163.27% |
33 Year Change | -79.29% |
5 Year Change | -91.40% |
Change since IPO | -91.94% |
Recent News & Updates
Shareholder Returns
SPRINT | SE Biotechs | SE Market | |
---|---|---|---|
7D | -10.2% | -2.4% | -4.3% |
1Y | 163.3% | 18.0% | 12.6% |
Return vs Industry: SPRINT exceeded the Swedish Biotechs industry which returned 18% over the past year.
Return vs Market: SPRINT exceeded the Swedish Market which returned 12.6% over the past year.
Price Volatility
SPRINT volatility | |
---|---|
SPRINT Average Weekly Movement | 8.9% |
Biotechs Industry Average Movement | 8.7% |
Market Average Movement | 5.8% |
10% most volatile stocks in SE Market | 12.2% |
10% least volatile stocks in SE Market | 3.4% |
Stable Share Price: SPRINT has not had significant price volatility in the past 3 months.
Volatility Over Time: SPRINT's weekly volatility has decreased from 40% to 9% over the past year, but is still higher than 75% of Swedish stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2009 | 36 | Johan Emilsson | www.sprintbioscience.com |
Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. It develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; and PETRA01, a drug candidate for the treatment of cancer. The company also focuses on research of products for the treatment of tumor metabolism, nash, and diabetes.
Sprint Bioscience AB (publ) Fundamentals Summary
SPRINT fundamental statistics | |
---|---|
Market cap | SEK 90.07m |
Earnings (TTM) | SEK 8.77m |
Revenue (TTM) | SEK 69.56m |
10.3x
P/E Ratio1.3x
P/S RatioIs SPRINT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
SPRINT income statement (TTM) | |
---|---|
Revenue | SEK 69.56m |
Cost of Revenue | SEK 13.63m |
Gross Profit | SEK 55.93m |
Other Expenses | SEK 47.15m |
Earnings | SEK 8.77m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 0.13 |
Gross Margin | 80.41% |
Net Profit Margin | 12.61% |
Debt/Equity Ratio | 0% |
How did SPRINT perform over the long term?
See historical performance and comparison